The Russian cancer vaccines (like Enteromix for colorectal/glioblastoma/melanoma and NeoOncovac mRNA for melanoma) are experimental and in early clinical trials. Phase 1 data from 2025 showed 100% immune response in ~48 volunteers, but no long-term results exist yet—efficacy, survival rates, recurrence prevention, or safety beyond 1-2 years aren't available. Larger Phase 2/3 trials (planned for 2026+) are required for that. First patient doses in Russia are slated for May at earliest.
No comments:
Post a Comment